Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
rare diseases
Biotech
Vigil's rare brain disease drug flunks phase 2 study
The trial missed its biomarker and efficacy endpoints, prompting the Sanofi-bound biotech to stop a long-term extension trial of the TREM2 agonist.
Nick Paul Taylor
Jun 4, 2025 9:45am
Fierce Pharma
Sanofi buys Blueprint for $9.1B, its largest deal in 7 years
Jun 2, 2025 11:09am
Stealth CEO questions FDA rejection of rare disease drug
May 29, 2025 2:27pm
Stealth hit by FDA rejection to twice-delayed filing
May 29, 2025 7:46am
BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect
May 16, 2025 8:46am
FDA delays decision on Biohaven troriluzole filing, plans adcomm
May 15, 2025 6:02am
